Skip to search formSkip to main contentSkip to account menu

tarextumab

A monoclonal antibody directed against the Notch receptor with potential antineoplastic activity. Tarextumab binds to Notch on the cell surface… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Monoclonal Antibodies

Narrower (1)

OMP-59R5
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract 1727: Circulating Tumor Cells (CTCs) in patients with extensive stage small cell lung cancer and their association with clinical outcome
Background: The NOTCH pathway has been identified as a key therapeutic pathway in SCLC. Tarextumab (TRXT, anti-Notch2/3, OMP-59R5… 
2016
2016
Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC…
8564Background: Notch signaling is implicated in cancer stem cell self-renewal and proliferation, thus it is an appealing target… 
2016
2016
Abstract A41: Use of patient-derived tumor xenografts (PDX) for discovery and development of an anti-Notch2/3 monoclonal antibody targeting cancer stem cells
Accumulating evidence has suggested that tumors may arise and grow as a result of the formation of a subset cell population… 
Review
2016
Review
2016
Abstract A42: Using a PDX tumor bank to screen for cancer stem cell therapies
OncoMed Pharmaceuticals is focused on discovering novel therapies that target cancer stem cells (CSCs), specifically those which… 
2015
2015
Tarextumab Gets FDA Orphan Drug Designation for Lung, Pancreatic Cancer
The US Food and Drug Administration has granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and… 
2015
2015
Abstract 2323: Tarextumab (Anti-NOTCH2/3) reverses NOTCH2 and NOTCH3-dependent tumorigenicity and metastases in small cell lung cancer
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Small cell lung cancer (SCLC) is marked by… 
2014
2014
465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)